Intel stock extends gains after report of possible U.S. government stake
NEW JERSEY - Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has regained compliance with Nasdaq’s minimum bid price requirement after maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days from June 20 to July 3, 2025, the company announced Tuesday. The stock, currently trading at $4.71, has shown remarkable momentum with a 299% gain over the past six months, according to InvestingPro data.
Following the compliance notification from Nasdaq, the previously scheduled hearing before the Nasdaq Hearing Panel has been canceled. The biopharmaceutical company’s securities will continue to be listed and traded on the Nasdaq Stock Market. InvestingPro analysis shows the stock has been quite volatile, with a beta of 3.08, suggesting higher risk-reward potential compared to the broader market.
"We are pleased to have regained compliance with Nasdaq’s minimum bid price requirement," said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals in the company’s press release. With a market capitalization of $337 million and moderate debt levels, the company maintains operational flexibility despite current financial metrics indicating the stock is trading above its Fair Value.
Citius Pharmaceuticals focuses on developing and commercializing first-in-class critical care products. The company received FDA approval for LYMPHIR in August 2024, a targeted immunotherapy initially indicated for treating cutaneous T-cell lymphoma.
The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief. Pivotal trials for both products were completed in 2023, with Mino-Lok meeting its primary and secondary endpoints in Phase 3 testing.
Citius Pharmaceuticals owns 92% of Citius Oncology and is currently working with the FDA to determine next steps for its Mino-Lok and Halo-Lido programs.
In other recent news, Citius Oncology is making strides toward the commercial launch of its FDA-approved immunotherapy, LYMPHIR, for cutaneous T-cell lymphoma, set for the second half of 2025. The company has completed commercial-scale manufacturing and established distribution agreements to ensure nationwide delivery. Meanwhile, Citius Pharmaceuticals, the parent company of Citius Oncology, has announced a registered direct offering expected to generate $6 million in gross proceeds. The funds are intended to support the launch of LYMPHIR and other corporate purposes. Additionally, Citius Oncology has entered into a distribution agreement with Cardinal Health to facilitate the U.S. launch of LYMPHIR. This partnership aims to ensure efficient access to the treatment for healthcare providers and patients. Citius Pharmaceuticals’ portfolio also includes late-stage products like Mino-Lok and CITI-002, which have completed clinical trials. These developments highlight Citius Oncology’s and Citius Pharmaceuticals’ ongoing efforts to expand their market presence and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.